This implies that passive immunization with tau antibodies is really a feasible therapeutic goal and the CSF standard of p-tau262/356 or of the microtubule binding domain (MTBD) can serve as a helpful biomarker of tau pathology to monitor tau therapeutics in scientific trials. Even with these pro